Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00251459 |
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
Condition | Intervention | Phase |
---|---|---|
Choroidal Neovascularization Age-Related Macular Degeneration |
Drug: rhuFab V2 (ranibizumab) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
Estimated Enrollment: | 5000 |
Study Start Date: | November 2005 |
Study Completion Date: | September 2007 |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | FVF3689g |
Study First Received: | November 8, 2005 |
Last Updated: | September 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00251459 History of Changes |
Health Authority: | United States: Food and Drug Administration |
SAILOR CNV AMD CNV secondary to AMD |
Uveal Diseases Metaplasia Eye Diseases Choroid Diseases Neoplasm Metastasis |
Retinal Degeneration Macular Degeneration Neovascularization, Pathologic Retinal Diseases Choroidal Neovascularization |
Uveal Diseases Pathologic Processes Metaplasia Eye Diseases Choroid Diseases |
Retinal Degeneration Macular Degeneration Neovascularization, Pathologic Retinal Diseases Choroidal Neovascularization |